Treatment Options for High-Risk, Clinically Localized Prostate Cancer
July 20th 2022Dr Stephen Freedland outlines the currently available, NCCN-recommended treatment options for patients with high-risk, clinically localized prostate cancer, and the clinical challenges he faces during the treatment decision-making process.
For Medicaid-insured patients with cancer, health insurance does not always mean health access
July 19th 2022“We found that Medicaid acceptance differed widely across cancer care facilities," said Michael Leapman, MD, MHS, associate professor of Urology, clinical program leader for the Prostate & Urologic Cancers Program at Yale Cancer Center and Smilow Cancer Hospital.
Pivotal olaparib/abiraterone mCRPC data published in New England Journal of Medicine Evidence
June 22nd 2022The phase 3 PROpel trial showed that adding the PARP inhibitor olaparib to frontline abiraterone acetate significantly improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.
UCSF prostate cancer specialist inducted into annual class of Giants of Cancer Care
June 21st 2022Eric J. Small, MD, has been announced as one of the winners of the 10th annual Giants of Cancer Care awards. Small is being recognized for his achievements in the clinical practice and research of genitourinary cancers.